Cardiovascular events and intensity of treatment in polycythemia vera

Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Rossella Cacciola, Riccardo Cavazzina, Daniela Cilloni, Valerio De Stefano, Elena Elli, Alessandra Iurlo, Roberto Latagliata, Francesca Lunghi, Monia Lunghi, Rosa Maria Marfisi, Pellegrino Musto, Arianna Masciulli, Caterina Musolino, Nicola Cascavilla, Giovanni Quarta, Maria Luigia Randi, Davide RapezziMarco Ruggeri, Elisa Rumi, Anna Rita Scortechini, Simone Santini, Marco Scarano, Sergio Siragusa, Antonio Spadea, Alessia Tieghi, Emanuele Angelucci, Giuseppe Visani, Alessandro Maria Vannucchi, Tiziano Barbui

Research output: Contribution to journalArticlepeer-review


Background: Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods: We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit,

Original languageEnglish
Pages (from-to)22-33
Number of pages12
JournalNew England Journal of Medicine
Issue number1
Publication statusPublished - Jan 3 2013

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cardiovascular events and intensity of treatment in polycythemia vera'. Together they form a unique fingerprint.

Cite this